From Retirement to Revolutionary Mission: The Birth of GPC Lifesciences
Retirement typically signals the end of professional pursuits, a time when individuals step back to enjoy their golden years. However, for Purna Chandra Ray, retirement marked the beginning of an ambitious new chapter—one aimed at addressing a critical vulnerability in India’s pharmaceutical and chemical sectors. In 2020, Ray founded GPC Lifesciences with a clear mission: reduce India’s overwhelming dependence on chemical imports from China.
This bold initiative was not born from mere audacity but from decades of hands-on experience working across various roles in pharmaceutical companies. Through his extensive career, Ray developed an acute understanding of the precarious position in which China’s dominance had placed India’s pharmaceutical and chemical manufacturing ecosystems.
The Chinese Stranglehold on Indian Pharma
Ray explains the depth of the challenge: “China dominates our chemical and pharma industry mainly because they are leaders in the manufacture of intermediates and active pharmaceutical ingredients (APIs). Even to manufacture paracetamol, our pharma companies have to import intermediates from China. At every step, Indian pharmaceutical and chemical companies are dependent on China. So, when I retired, I thought why not work on this so that we can reduce our import bill?”
This dependency creates significant strategic and economic vulnerabilities for India’s pharmaceutical sector. The country’s inability to produce critical intermediates domestically means that supply chain disruptions, geopolitical tensions, or price manipulations by foreign suppliers can severely impact domestic drug manufacturing and affordability.
Identifying and Bridging the Innovation-Production Gap
The Disconnect Between Research and Reality
Ray identified a fundamental problem plaguing India’s pharmaceutical and specialty chemical ecosystem: “There’s a big gap between India’s pharmaceutical and speciality-chemical ecosystem. While the country possesses strong scientific talent, it has a persistent dependence on imported technologies and intermediates, particularly for complex chemistries. At the same time, many innovations struggled to move from laboratory scale to reliable commercial production.”
GPC Lifesciences was specifically designed to bridge this critical gap between process innovation and industrial manufacturing reality. The company’s approach differs fundamentally from traditional academic or research-focused chemistry development.
Manufacturer-Centric Chemistry Development
“The idea was rooted in practical experience,” Ray emphasizes. “We wanted to build a company that approaches chemistry from a manufacturer’s perspective—focused on scalability, cost, safety, and regulatory compliance. Rather than developing chemistry for academic validation, we wanted to focus on developing processes that work consistently at plant scale and make commercial sense.”
This practical, manufacturing-oriented approach ensures that laboratory innovations can successfully transition to commercial-scale production without the common pitfalls of cost overruns, safety issues, or quality inconsistencies.
Developing Affordable Drug Manufacturing Processes
Regulatory Framework Supporting Innovation
Ray’s co-founder Singh, also a retired pharmaceutical professional who joined the venture in 2025, explains the regulatory landscape that makes GPC Lifesciences’ mission viable: “In the pharma industry, most innovative branded drugs have traditionally come from Western countries, especially the US, Europe, and Japan, given that new drug molecule discovery is an expensive affair. These patented drugs are quite often unaffordable to most people. But in 1994, the Government of India passed a regulation that, if the same drug can be manufactured by a different process, then it stays out of the Intellectual Property Rights’ ambit.”
This regulatory provision creates space for companies like GPC Lifesciences to develop alternative manufacturing processes for existing drugs, making them more affordable without violating patent protections.
Addressing Orphan Drug Accessibility
Singh highlights another critical area: “These are drugs that are used by a small percentage of the population, largely because the illness impacts a small number. Many genetic diseases fall in this category. Often, the treatment for such diseases as Spinal Muscular Atrophy (SMA) can go up to lakhs of rupees per month, which makes it unaffordable to most.”
Developing cheaper manufacturing processes for drugs that help patients, particularly those suffering from rare diseases, became a cornerstone objective for GPC Lifesciences. By reducing production costs, the company aims to improve accessibility to life-saving medications for underserved patient populations.
Investing Retirement Savings for National Impact
Personal Financial Commitment
Armed with a doctorate in organic chemistry and deep industry knowledge, Ray possessed the technical expertise to create new processes and molecules beneficial to India’s pharmaceutical industry. However, transforming knowledge into action required substantial financial investment.
Driven by unwavering determination and belief in his mission, Ray made a momentous decision: he invested his entire retirement savings into launching GPC Lifesciences. “I used ₹50 lakh of my savings to start GPC Lifesciences in 2020,” Ray reveals. This personal financial sacrifice demonstrates the depth of his commitment to reducing India’s import dependency.
For most retirees, such savings represent security and comfort for their remaining years. Ray’s willingness to risk these funds underscores both his confidence in the venture’s viability and his dedication to solving a national challenge.
Building Infrastructure and Strategic Partnerships
Overcoming Infrastructure Constraints
Ray had clear ideas about developing specific molecules and processes beneficial to the pharmaceutical industry. His initial focus centered on para-aminophenol (PAP), a critical intermediate used in manufacturing paracetamol, one of the world’s most commonly consumed medicines.
However, a significant obstacle emerged: Ray lacked the laboratory setup necessary for process development and could not afford to build one independently. Rather than abandoning his vision, he sought creative solutions.
Leveraging NCL Innovation Park
Ray discovered NCL’s Innovation Park and its associated Venture Centre, which provided the infrastructure he desperately needed. “So I tied up with Venture Centre that had labs, clean rooms and all the facilities one needs to run a process or develop cost-effective processes for generic molecules,” he explains.
This partnership arrangement allowed GPC Lifesciences to access world-class laboratory facilities without the prohibitive capital investment required to build them from scratch.
Securing Raw Material Supply
Process development requires reliable access to raw materials, most of which for the chemical industry derive from petroleum byproducts. Fortunately, Ray’s extensive professional network proved invaluable. “I had several contacts in the industry during my professional years, so I could procure petrochemical waste from a petrochemical company based in the northern part of India,” he notes.
This connection enabled GPC Lifesciences to secure essential raw materials cost-effectively, providing a crucial competitive advantage in process development.
Process Innovation and Successful Molecule Development
Para-Aminophenol (PAP) Development
Ray began his development work with benzene, a highly carcinogenic compound that, when converted to its derivative or intermediate form, loses its carcinogenic properties. “The conversion of benzene to PAP is a three-step process that is high on energy consumption, manpower and chemicals,” Ray explains.
His goal was ambitious yet specific: develop a more efficient PAP production process that could compete directly with Chinese manufacturers on cost and quality.
Expanding the Molecule Portfolio
Beyond PAP, Ray identified metformin and other commercially important molecules. Utilizing the laboratory facilities at NCL Innovation Park, GPC Lifesciences achieved remarkable success within three years, developing ten molecules including paracetamol, acotiamide, linagliptin, and their intermediates, along with optimized manufacturing processes for each.
Process Redesign Philosophy
Simply put, GPC Lifesciences redesigns chemical processes to make them safer, cheaper, and easier to manufacture at large scale. “Often this involves reducing the number of steps, replacing expensive or imported materials with locally available alternatives, and improving reaction efficiency,” Ray explains. “The goal is to ensure that what works in a laboratory flask also works in a large industrial reactor.”
This pragmatic approach addresses one of the pharmaceutical industry’s most persistent challenges: translating laboratory-scale success into commercially viable, large-scale production.
Navigating Funding and Scalability Challenges
The Capital Constraint
Despite Ray’s personal investment of ₹50 lakh, the company required substantially more funds to achieve commercial scale. GPC Lifesciences has applied for various government grants but has faced difficulties in securing them.
Singh shares their ongoing efforts: “This year we have filed three applications for funds to support our research and development activities. I hope we receive some help.” The funding challenge represents a multifaceted problem that affects the company’s growth trajectory.
Market Confidence Despite Scale Limitations
Unlike many startups uncertain about market demand, GPC Lifesciences possesses strong market confidence. “Both founders are pharma industry veterans and have a large network of companies that we can tap into for sales,” Ray asserts.
This confidence is backed by concrete customer relationships. Their first customer was their colleague, Prof Ghosh of IIT Mandi, Himachal Pradesh. “They used our chemical azo derivative compound for their semiconductors,” Ray notes. Another customer purchased their process for using benzene and its derivatives to manufacture fine chemicals.
Ray summarizes their unique position: “We have access to markets but lack the corresponding scale to match it.” This situation represents both a challenge and an opportunity—proven demand awaits the company once it achieves sufficient production capacity.
Revenue Growth and Strategic Expansion Plans
Financial Performance and Projections
Following his initial ₹50 lakh investment, Ray successfully generated ₹1.22 crore in revenue during the last financial year. The company has set ambitious targets for continued growth. “This year we intend to have revenues of ₹3 crore,” Ray states, representing more than a 145% increase.
Capital Requirements for Scaling
GPC Lifesciences is actively pursuing funding through multiple channels, including MSME grants, Start-up India Funds, and the Promotion of Research and Innovation in Pharma (PRIP) scheme. The company seeks approximately ₹5 crore in funding to achieve critical operational milestones.
This capital would enable the company to purchase essential analytical instruments including High-Performance Liquid Chromatography (HPLC), Gas Chromatography (GC), and Karl Fischer (KF) titration capabilities. Currently, GPC Lifesciences must outsource these analytical tasks, creating inefficiencies and additional costs. In-house capabilities would significantly improve operational efficiency while reducing costs.
The funding would also support increased manpower and expanded rental laboratory space, enabling the company to handle more projects simultaneously and accelerate process development timelines.
Future Vision: Self-Reliant Manufacturing for Emerging Markets
Domestic and Regional Market Focus
Ray articulates a clear strategic vision for GPC Lifesciences’ market expansion: “There is a lot to do in the domestic market, going to the US is not on the cards as of now. But we do plan to target Southeast Asian countries and the 54 Islamic countries, as they urgently need to lower the cost of medicines. Later on, I may get into regulated markets like the US, but not yet.”
This phased approach prioritizes markets where affordable medicines create the most significant patient impact. Southeast Asian and Islamic countries often face similar challenges to India regarding medicine affordability and import dependency, making them natural markets for GPC Lifesciences’ cost-effective processes.
Measurable Import Reduction Goals
Ray has established specific, quantifiable objectives for the company’s impact: “We’re targeting about 10% reduction in imports of four molecules from other countries.” While this may seem modest, reducing imports by 10% for even four critical molecules would represent a substantial achievement given the scale of India’s pharmaceutical industry.
Age as Just a Number
The passion and dedication Ray and Singh bring to their mission rivals that of entrepreneurs decades younger. Their professional experience, industry networks, and technical expertise provide advantages that younger founders might lack. As Ray aptly concludes: “For the duo, age is just a number, truly.”
Their journey from comfortable retirement to founding a company addressing critical national challenges demonstrates that meaningful entrepreneurship knows no age limits. With proven technology, growing revenue, and expanding market relationships, GPC Lifesciences appears well-positioned to achieve its audacious goal of reducing India’s chemical import dependency while making medicines more affordable for patients worldwide.
